**Pharmacovigilance and Drug Safety in the Digital Age**

**I. Introduction**

**a. Definition and Importance of Pharmacovigilance**

The Australian physician W. McBride, who first hypothesized a connection b/w thalidomide, a medication used during pregnancy, and severe fetal abnormalities (phocomelia), officially established pharmacovigilance (PV) in December, 1961 with the publication of a letter in Lancet. In pregnant women, thalidomide was administered as an antiemetic and sedative [1]. PV is described by WHO as "the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or other potential drug-related problems [2]."The science of PV aims to minimize the chance that consumers will suffer damage as a result of using drugs. PV is the process of identifying pharmacological adverse effects, treating them, documenting, reporting, and making regulatory decisions in light of these results. PV, in its broadest sense, is the science of gathering, monitoring, analysing, and evaluating data from healthcare professionals and patients on AEs of pharmaceuticals, including herbal and conventional treatments. The global campaign to increase patient safety is gaining traction, making drug safety an even more important topic in the modern world. The practice of pharmacovigilance is expanding in India as well, keeping up with the times [3].

**b. Overview of Drug Safety in Digital Age**

Drug In order to track the occurrence of ADRs, post-marketing surveillance systems are necessary in every nation because domestically generated data may influence national regulatory policy. These initiatives might aid in a reduction in ADR-related morbidity, death, hospitalizations, medical expenses, and liability. The majority of ADRs frequently go unnoticed or unreported. A structured ADR monitoring program is one way to more actively discover ADRs, which will subsequently improve the standard of patient care. The numerous processes are used in minimizing harm to patients and thus enhancing public health [4]. This suggests a well-functioning Pharmacovigilance system in clinical practice. Pharmacovigilance, which was initially defined as "The detection in the community of drug effects, usually adverse," focused exclusively on keeping an eye on negative medication reactions in the early 1990s. Pharmacovigilance can be organized or passive, with the former involving the gathering of spontaneous reports. As it helps to avoid, identify, and evaluate adverse responses to medications intended for human use, pharmacovigilance is crucial for the protection of public health. It includes full life-cycle management of pharmaceuticals for human use while keeping safety in mind. We must therefore emphasize the importance of pharmacovigilance as a continuation and completion of the analysis conducted on medicines beginning from the clinical trials when the treatment is delivered for the first time in humans, and not simply after they have been launched [5-7]. The threat posed by the ever-growing list of medications, each of which carries an unavoidable risk of unanticipated potential for harm, is addressed in large part through pharmacovigilance. It is mandatory that adverse effects and toxicity be documented, examined, and their significance effectively communicated to those qualified to evaluate the information if they do occur, especially when they were previously unknown. By ensuring that therapeutic items of high quality, safety, and efficacy are utilized intelligently, the harm can be minimized. Additionally, when making therapeutic decisions, the patient's expectations and worries regarding results are taken into account. To achieve this goal and increase patient trust, make sure that medication usage risks are anticipated, effectively managed, and shared with regulatory bodies and other healthcare professionals [8,9].

The ways in which people interact with health-related information are being redefined by the Internet. In this digital age, using new media to communicate with patients and their support systems provides medical and public health professionals with an unmatched opportunity to find the information they require. Drug safety is one area where these skills may have broad, yet as-yet-unknown implications. Important questions have surfaced as the amount of health-related material on the Internet has increased [10]. We chose new drug-safety notifications pertaining to prescription medications that were released by the US FDA throughout a 2-year span between 1st January 2011, to 31st December 2012, in order to investigate these topics. We also created a baseline period for comparison that stretched from 60 days to 10 days prior to the time of interest. The prescription medications with indications for a variety of clinical diseases, such as primary hypertension, chronic myelogenous leukaemia, and hepatitis, were found to include safety warnings [11]. Over the course of the trial, these medications caused 13 million Google searches and 5 million Wikipedia page views. In comparison to baseline trends, FDA safety warnings were linked to an average 82% increase in Google searches for the drugs the week following the announcement and a 175% increase in views of the drugs' Wikipedia pages the day of the announcement. Did users discover reliable data about the safety of the drugs? We discovered that 41% of Wikipedia entries relating to medications with new safety warnings were updated with information from the FDA within two weeks of the warning's release. Wikipedia pages for medications intended to treat conditions with a high prevalence (more than 1 million Americans affected) were more likely to be updated quickly (58% within 2 weeks) than those for medications intended to treat conditions with a lower prevalence (20% within 2 weeks, etc.). On average, 42 days passed before a Wikipedia article was modified more than two weeks after the FDA issued its warning, and as of January 2014, 36% of pages were still unaltered after more than a year. Due to the FDA's decision to add a new black-box warning on this danger to the medicinal label, Google searches for the medication increased by 50% the following week and the number of views on its Wikipedia page increased by 141%. Additionally, they might know more about when to seek medical attention for signs of a possible medication reaction. When prescribing a medication, doctors can offer some crucial information, but the Pew survey reveals that many patients still independently consult other sources [12,13]. The FDA's "Dear Health Care Provider" letters and printed drug labels have historically been the focus of public health officials, but new technologies give them the chance to communicate with patients and doctors more effectively and efficiently. We think the first move should be to make the drug information on the FDA website more easily accessible. Currently, electronic drug labels providing data on effectiveness, dosage, and contraindications are used instead of the MedWatch to house safety communications [14-15].

c. Evolution and Impact of Technologies on Pharmacovigilance

Due to issues with regulatory compliance, data privacy, interoperability, and the perceived interruption to current PV operations, digital adoption within pharmacovigilance has generally been uneven. The journey so far has primarily focused on setting the groundwork. The sector is now prepared to take advantage of the earlier work and quicken the implementation of digital technology. To assure the success of such a venture, however, wise decisions and meticulous procedures are required. However, technology has steadily advanced in pharmacovigilance throughout time, making it simpler and more effective for businesses to track and report adverse drug reactions. Pharma businesses are gradually feeling more at ease putting their PV data in external data centres as safe and affordable hosted data centres become available. This was a crucial step that served as a milestone in our technological journey's quick evolution [16-19].

**Traditional Pharmacovigilance Methods**

**a. Adverse Drug Reactions (ADR) Reporting Systems**

Worldwide, adverse drug reactions constitute a major cause of illness and mortality. ADRs account for 6.5% of hospital admissions in the UK, posing significant health, financial, and labor costs [20]. In order to centralize global data on adverse drug reactions, the WHO developed the "Programme for International Drug Monitoring" in 1968. The "WHO Programme" has the specific objective of locating the first PV indications. A group of French Pharmacologists and Toxicologists coined the word PV in the middle of the 1970s to describe the actions supporting "the assessment of the risks of side effects of potential drug treatment [21-23]."

"Even a strong poison can become an excellent medicine if used properly," says Charaka. However, if used carelessly, even the most beneficial medicine might become poisonous. A harmful and unanticipated reaction to a health product that has been marketed that takes place at dosages typically tested for the diagnosis, treatment, or prevention of a disease or change of biological function is known as ADRs [24-27].

Throughout the whole life cycle of a product, post-marketing PV and clinical trial safety are both essential. The pharmaceutical business and regulatory organizations have increased the bar in response to a number of recent high-profile drug withdrawals. Major pharmaceutical companies are now implementing robust risk management plans throughout the life cycle of the product in order to identify the risks associated with the medicinal product and effectively manage the risks by using early signal detection from both clinical trials and post-marketing surveillance studies. PV has taken on a new dimension with the addition of signal detection and risk management, and as a discipline that is still developing, it still has to be improved in order to be more applicable and valuable to public health. The PV Program of India is aimed to gather, compile, and analyze data in order to draw conclusions and suggest regulatory measures to affirm the healthcare workers and people about hazards [28,29].

The largest global centers for the development of pharmaceuticals have strict regulations governing pharmacovigilance. The three main regulatory organizations that are in charge of regulating worldwide pharmacovigilance are the European Medicines Agency, FDA, and Pharmaceuticals and Medical Devices Agency. To prepare the organizational structure, assign duties, and processes as well as to create the competencies required to carry out pharmacovigilance effectively, guidelines, legislation, regulations are put in place. National laws and ordinances in Europe and the United States, as well as the Code of Federal Regulations, are both enforceable. There are three pharmacovigilance programs that are accepted globally: the European Union program, the WHO Uppsala Monitoring Centre program, and ICH program. They each have different pharmacovigilance traits, yet they could all lead to safe clinical medication usage. In recent years, the approval for novel pharmaceuticals has been accelerated, given top priority, and reviewed quickly. The advent of fast and conditional approval pathways necessitates new pharmacovigilance procedures as well as more frequent and innovative risk management techniques. The FDA has implemented additional procedures to address the new issues [30,21].

**b. Reporting of Adverse Events**

The cornerstone of pharmacovigilance is the reporting of adverse events, which is why regulatory bodies regularly monitor it. The following are the definitions provided by ICH E2A for AEs, ADRs, and serious AEs [32].

1. **Adverse event**

Any undesirable medical event in a patient or clinical research subject given a pharmaceutical substance, even though it doesn't necessarily have to be related to this treatment. A negative and undesired sign & symptoms that are temporally linked to the use of a pharmaceutical product might therefore be termed an adverse event (AE), whether or not it is thought to be related to the medicinal product (including, for example, an aberrant laboratory finding) [33].

1. **Adverse drug reaction**

All unpleasant and unexpected reactions to a drug associated to any dose should be recognized as adverse drug reactions, especially since the therapeutic dose (s) may not be known. The term "responses to a medicinal product" denotes that there is at least a remote potential that a medicinal product caused an unfavorable event; in other words, the relationship cannot be ruled out [34].

### **Pharmacovigilance in clinical trials**

### Everywhere, clinical trials are used to determine the safety and effectiveness of a chemical or biological compound in relation to its effects on marks or a known disease process. Clinical trials that give information on the risks and benefits of the medicine are a driving force behind pharmacovigilance. Clinical research pharmacovigilance seeks to determine whether benefits outweigh dangers; if they do, drug producers take action to secure approval to commercialize the new drug. A scientist and the pharmaceutical corporation involved in creating a therapeutic product closely monitor trials. However, the procedure also gains from an impartial assessment by drug safety companies. This approach is complemented by pharmacovigilance, which adds an extra layer of protection to ensure that only safe and effective medications are used on patients. The implementation of the finest treatment for patients and customers internationally is the responsibility of medication developers, producers, pharmaceutical systems, and investigators as part of the global healthcare system [35].

### Before a pharmaceutical company may request the market authorization of a novel drug, phase I, phase II, and phase III clinical trials are required. They are in charge of managing the research, and they report back to the sponsor (the pharmaceutical business). The analyst collects and examines significant adverse events (SAEs) that occur during clinical trials to determine whether the medicine in question is to blame. Adverse drug responses (ADRs) are what they are called if they determine that the negative side effects were caused.

### The pharmaceutical corporation in charge of the research and development of the medicine receives this information from the analyst. The patient files are subjected to a medical review, and it is mandated by the pharmaceutical company's internal PV team. To go on to the next phase of clinical research or to file an application to the regulatory authority for authorisation to go on the market, the PV team determines whether the drug is safe and effective. Upon approval, the pharmaceutical business may start Phase IV clinical trials to gather further information on the effectiveness and safety profile. These studies provide information about drug usage by patients in a less controlled setting [36-38].

### **What is the pharmacovigilance role in clinical research?**

### PV in clinical trials is required to update the potential dangers of drugs for consumers and healthcare providers. As it is impossible to foresee all potential negative effects of a drug based on pre-approval studies, the drug firm may support post marketing drug safety surveillance to observe the product's safety and effectiveness in the real world. There are many strategies that can be used, including electronic health records, spontaneous reporting systems, and drug registries [39].

### **Why is pharmacovigilance important?**

Pharmaceutical companies can learn more about a drug's safety profile thanks to PV analysis carried out throughout Phase I, Phase II, and Phase III clinical studies. This information can be suggested to regulatory authorities to access new markets or used for additional R&D if necessary.

Clinical research PV techniques provide important insights into the safety profile of pharmaceutical drugs. The list of side effects on the label needs to be updated whenever a specific adverse event is identified. Sometimes, PV data can force a drug recall because of potentially fatal adverse effects. A better risk-benefit ratio is maintained, tracked, and modified as necessary. The pharmaceutical business may carry out phase IV trials to monitor the medication on a much bigger scale and in a less controlled real-world setting after finishing Phase III clinical trials and receiving marketing permission [40-43].

It is noteworthy that efficient, pertinent training is crucial to overall professional development. Having the appropriate information is crucial in highly specialized businesses like clinical research. Clinical trials have significantly increased in both industrialized and developing nations in recent years. Between 1990 and 1998, the number of clinical studies conducted in the United States alone than doubled. Clinical research on potential novel pharmacological therapies is projected to grow considerably more as a result of the sequencing of the human genome [44-47]. A growing partnership exists between academia and the biotechnology and pharmaceutical businesses. This has caused grave and widespread worry regarding moral and scientific matters like [48,49]-

1. possibility of a conflict of interest
2. unethical patient recruitment techniques
3. inadequate informed consent
4. inability to guarantee ongoing clinical trial monitoring
5. adherence to ethical and sound clinical practice standards
6. in-adequate reporting and management of adverse events.

The growing patterns in clinical trial conduct over the past few years have given drug regulators particular and urgent problems, particularly in ensuring the protection of patients' rights and health as well as those of their communities. Before approving clinical trials, regulatory organizations take the safety and efficacy of novel products under investigation into account. They must be aware of the general standards of care and the security of study participants in addition to the required institutional review boards (IRBs). prescription medicines for diseases like tuberculosis, HIV/AIDS, malaria, and meningococcal Meningitis and those that may have a problematic or confusing effectiveness-safety profile necessitate special supervision when first being introduced on a broad scale to populations. The intricacy of clinical studies presents significant challenges for regulators. Safety monitoring during clinical trials is currently recognised as one of the major challenges for the development of innovative medications. Assuming complete information exchange between regulatory authorities and ethical committees (institutional review boards) and the investigators and sponsors, a standardized reporting system for safety issues raised during clinical trials could be a useful tool. The reporting process has been made a little easier in ICH countries thanks to expedited electronic submission of safety reports [50-52].

Signal Detection and Risk Assessment

The goal of the signal management procedure in pharmacovigilance is to identify any new risks connected with a given medicinal product or any recognized dangers linked with a certain medicine that have altered in frequency or severity. Signal identification, Signal Validation, and Signal Reduction comprise the systematic method to signal management. Prioritizing signals, evaluating signals, recommending actions, and exchanging information are the last steps. The most important aspect of signal management is signal detection. Traditional approaches use isolated algorithms without any additional qualitative data mining elements, which leads to subpar results. The development of the quantitative and qualitative detection algorithms requires significant work. To get around this restriction, we developed a hybrid technique where the algorithm is fueled to evaluate a signal and also manage it for efficient grading based on a qualitative approach. The current essay gives a thorough and in-depth explanation of our hybrid methodology. All medications that have been given the go-ahead to be administered in a controlled environment have been shown to have advantages while also having disadvantages. To guarantee patient safety, it's critical to identify these unidentified dangers. In order to identify case reports of adverse events (AE) that are worthy of further investigation, individual case safety reports (ICSR) must be continuously monitored as part of the signal identification and management process in pharmacovigilance. Signals are often detected quantitatively or qualitatively. Comparative detection uses statistical methods such disproportionality analysis, whereas qualitative detection requires a manual assessment of the ICSR in an individual or cumulative manner. In pharmacovigilance, the signal management process involves a number of actions that assess the hazards connected to a certain pharmaceutical medication. The most important aspect of signal management is signal detection. The hybrid approach was developed by TCS scientists, who use an algorithm to evaluate a signal and also manage it for efficient grading using a qualitative approach. We give a thorough and in-depth explanation of this hybrid technique in this work [53-56].

##### **Digital Technologies in Pharmacovigilance**

1. **Role of Big Data and Real-World Evidence**

#### As Contract research organizations (CROs) progressively embrace digital transformation, the usage of conventional paper-based case record forms (CRFs) is becoming obsolete. This allows for greater data quality and dependability, security in pharmacovigilance, cooperation, innovation, and speed of processing. As Contract research organizations increasingly embrace digital transformation, the use of conventional paper-based case record forms (CRFs) is becoming obsolete. This allows for greater accuracy and reliability of data, security in pharmacovigilance, collaboration, innovation, and speed of operations. Life science organizations are increasingly feeling the effects of pharmacovigilance (PV). Large pharmaceutical businesses deal with an average of 700,000 adverse event (AE) incidents yearly, according to EY research1, and IDC2 has discovered that this figure is fast rising by 30 to 50% annually. The pandemic has made the problem worse, and some industry participants are now dealing with more over one million AE cases annually due to the quick tracking of COVID-19 vaccinations. Companies are under pressure to successfully handle this rising caseload while keeping their current cost structure. Data sources are multiplying, making it difficult for safety teams to go through the chaos of data points to provide insightful findings while simultaneously satisfying various regulatory requirements for safety reporting. As a result, costs for PV departments have skyrocketed [57-59].

#### A real-world data and real-world evidence play an increasingly essential role in clinical research. Electronic health records are a useful source of information. However, there are also considerable obstacles to using and interpreting EHR data correctly, such as bias, population heterogeneity, and missing or unstandardized data formats [60].

#### **b. Social media and Patient reported data**

Enrolment in clinical trials and patient assistance initiatives. It offers new channels and techniques that can help businesses switch from conventional PV systems and safety reporting procedures to more patient-centric models for reporting, examining, and tracking safety data. Any potential AE reports shared through online forums must be documented and followed up on by biopharmaceutical companies that use social media, in accordance with the relevant regulatory advice. The majority of regulatory directives, and consequently PV operations involving social media and the internet, are centered on monitoring social media sites and reported safety data. Grading of Recommendations, Assessment, Development and Evaluations criteria were used to evaluate the methodological quality of the studies. Information about the safety of medications is increasingly coming from patients. The information is obtained directly from those who have personally experienced the negative drug responses by employing patients as a source. Compared to information from healthcare professionals, these experiences are richer in context and information on the impact of an ADR. The gathering of patient reported information is becoming simpler and more economical thanks to new technology [61].

**c. Wearable Devices and Sensor Technologies**

Wearable devices are attracting a lot of interest because of they provide real-time physiological data in a range of healthcare related applications through dynamic and non-invasive measurements of chemical markers in biofluids. Major advancements have been made recently in this field, with recent breakthroughs concentrating on electrochemical and optical biosensors. These include the development of microfluidic sampling and transport systems and multiplexed biosensing techniques, as well as system integration, downsizing, and flexible materials for improved wearability and ease of use. Modern wearable biosensing technologies' greater accuracy, efficacy, and utility are increasing their reliability and economic impact. Overall, significant large-population validation of wearable biosensor performance through interdisciplinary collaboration across the technical, biological, and clinical disciplines will be necessary in order for wearable biosensors to be widely accepted by the medical and commercial worlds. With smartphones and other devices, wearable sensors have drawn a lot of attention offering helpful insights regarding the performance and health of people. Early research in this field concentrated on physical sensors that tracked movement and vital indications like heart rate, steps taken, and calories burned. Researchers have moved away from tracking physical activity to concentrate on addressing significant problems in healthcare applications, such as the treatment of diabetes or remote monitoring of the elderly, changing the face of wearable technology quickly in recent years. A typical biosensor is made up of two basic functional components: a 'bioreceptor' (such as an enzyme, antibody, or DNA) that recognizes the target analyte with specificity and a physico-chemical transducer (such as an electrochemical, optical, or mechanical device) that converts this biorecognition event into a useful signal. Such devices were initially created for single-use home testing or for in vitro measurements in regulated environments. Due to their high specificity, speed, mobility, low cost, and low power needs, biosensors have a lot of potential for wearable applications. In fact, cutting-edge biosensor platforms for non-invasive chemical analysis of biofluids had well utilized.

**d. Mobile Health Applications for Drug Safety Monitoring**

By offering a proper environment to meet mobile health (mHealth) goals, mobile technology helps health care organizations to expand medical services, making some medical services accessible anywhere and at any time. The introduction of mHealth could alter the administrative procedures used to provide services to patients. As it becomes vital for patients to participate in the processes related to their healthcare, mHealth may empower them. This includes the capability for patients to control their personal data and communicate both with healthcare professionals and other individuals. The online health educator, a new position suggested by the study, would oversee mHealth services. Specialized healthcare workers with experience in running online services should work in the OHE. A focus group discussion with participants who engaged with OHE in a genuine online health scenario followed a survey that was carried out in Brunei and Indonesia to learn more about the roles of OHE in administering mHealth services. Data study revealed that OHE could raise patients' happiness and trust in medical services. mHealth, as the combination of mobile devices and health services is frequently termed, is often thought to revolutionize the use of information technology in healthcare due to the growing accessibility of mobile devices and the related applications, both for providers and patients. On the other side, users, providers, and operators who offer such solutions frequently face entirely new difficulties. This article evaluates the possibilities and promise of mHealth while also critically examining potential drawbacks. This critical examination is presented by three exemplary application areas because this topic is so broad: mHealth in radiology, the impact of mHealth on research, and mHealth as a catalyst for new services, always with examples from other nations. As mobile technology advances rapidly, the use of mHealth in radiology is currently frequently developed empirically from already-existing applications in an unstructured manner. The options range from teleradiology to radiologists having access to pictures at the patient's bedside via mobile technology.

Utilizing mHealth (mobile and wearable health information and sensing technology) creatively has the potential to lower healthcare costs and enhance wellbeing in a variety of ways. Numerous areas are developing these applications, but in-depth study is required to assess the advantages and disadvantages of using mobile technologies to enhance health outcomes. Evidence supporting the effectiveness of mHealth is still lacking. The Innovative Medicines Initiative WEB-RADR (Recognising Adverse Drug Reaction project) of the European Union investigated the value of two digital tools for drug safety over a three-year period: mobile applications for reporting drug side effects and social media data for its role in safety signalling. The main goal of WEB-RADR was to offer recommendations on developing and using such digital tools to improve patient safety from a policy, technical, and ethical standpoint.

e. Artificial Intelligence and Machine Learning in Pharmacovigilance

The most well-known technologies at the moment are machine learning and artificial intelligence. They are advancing pharmacovigilance while having a wide variety of uses. Here, we'll look into the Pharmacovigilance phenomenon. We can see how artificial intelligence and machine learning in pharmacovigilance are revolutionizing the field and adding more value through use cases and prospects. As a result, patients will receive better care, better medicine, and new revenue streams.

The Benefits of Machine Learning and Artificial Intelligence in Healthcare AI is a field of study that aims to replicate human intelligence. It can aid in the management of complicated and multidimensional data. In response, ML makes use of both conventional and deep learning techniques. It enables the creation of precise classifications of data points and the ability to make precise predictions. Combining AI and ML is ideal for making sense of massive amounts of data. Businesses can use AI and ML in a variety of sectors and industries. Implementations of AI and ML are also apparent in the healthcare sector as their use accelerates. According to USM Systems research, half of all healthcare organizations worldwide intend to use AI by 2025.

### **f. AI and ML in Pharmaceuticals**

Drug discovery requires working with a vast amount of data. ML and AI can help in this situation. Here is an example of how the pharmaceutical industry is prepared for further AI implementation. According to Statista, 59 startups are utilizing AI to produce new drug development ideas. The leading application for AI and ML is still drug development, but there are other noteworthy fields as well. Key factors are its potential for growth and profitability. According to this study, the worldwide AI industry for drug development would grow from $259 million in 2019 to $1,434 billion by 2024. The predicted yearly growth rate is 40.8%. More details about digitalization in drug discovery can be found here.

**g. Automated Signal Detection and Analysis**

Modern culture is dominated by medications, yet in addition to their medicinal benefits, drugs can have side effects that range from minor to morbid. Pharmacovigilance is the process of gathering, detecting, evaluating, monitoring, and preventing adverse medication occurrences during clinical trials as well as after a product has been put on the market. The need to create an optimal system for monitoring and timely signal detection has increased due to current trends in the rise of unforeseen bad events, also known as signals. The procedures used to systematically detect individual case safety reports are part of the signal management process. Automated signal detection has a strong foundation in data mining of spontaneous reporting systems, including reports from medical practitioners, observational studies, medical literature, and social media. A signal can become a risk similar to that of the medication if it is not managed appropriately, which could be risky for patient safety and lead to fatalities, which could have a detrimental impact on the healthcare system. Once a signal has been quantitatively recognized, the signal management team may continue processing it for the qualitative analysis and subsequent evaluations. The fundamental components of automated signal detection include data extraction, data acquisition, data selection, data processing, and data assessment. This system needs to be designed in the appropriate context and format, which emphasizes the caliber of data gathered and ultimately results in the best decisions based on scientific analysis.

**h. Natural Language Processing for ADR Detection**

Hospitals require a system to assist them in frequently, quickly, and broadly monitoring the occurrence of ADEs in order to decrease them. ADE identification has become very convenient through pharmacovigilance, natural language processing and a computer. However, there is a dearth of a thorough qualitative evaluation and critical assessment of NLP techniques for ADE identification in the context of ADE monitoring in hospitals. In order to fill this knowledge gap and offer recommendations for future research and practice, we conducted a scoping review. We incorporated studies that used NLP to identify ADEs in clinical narratives found in inpatients' electronic health records. NLP-related quantitative and qualitative data items were extracted and evaluated rigorously. 29 articles that were evaluated for eligibility out of 1,065 articles satisfied the requirements for inclusion. Named entity recognition (n = 17; 58.6%) and relation extraction/classification (n = 15; 51.7%) were the activities that were performed the most frequently. Nine studies (31%) reported clinical involvement. Numerous NLP modeling strategies appear appropriate, with Conditional Random Field and Long Short-Term Memory techniques being the most frequently utilized ones. Although the systems' claimed overall performance was strong, this impression is overstated given a sharp decline in performance when predicting the ADE entity. The optimal method when annotating corpora appears to be to treat an ADE as a relation between a drug and non-drug object. Future studies should study how to implement NLP techniques in real-world settings and concentrate on semi-automated techniques to lessen the manual annotation work.

**i. Predictive Analytics and risk Assessment Models**

Predictive analysis and the creation of predictive models are beginning to replace simple descriptive analysis as drug safety and pharmacovigilance organizations gain more advanced data analytics skills. In many facets of medicine and health care, predictive analytics makes forecasts of future outcomes or trends using present data. The most effective way to demonstrate the significance of anticipating (adverse) events is through the framework of signal detection and the identification and characterization of individuals with a specific risk of experiencing an adverse event after being exposed to a medicine, both in clinical development and in post-marketing settings.

**Identifying dangers from unprompted reports**

In pharmacovigilance reports, predictive modeling can be used to find previously undiscovered drug dangers. VigiRank, a data-driven predictive model for emerging safety signals, is a good illustration of this use since it has been demonstrated to outperform disproportionality analysis alone in real-world pharmacovigilance signal detection5. In VigiBase, where predictive models have been shown to be helpful in identifying safety signals that were ultimately verified, VigiRank is to be used in pediatric populations.6

**An analysis of an unanticipated rise in reporting frequency**

Similar to this, the European Medicines Agency created an algorithm to identify sudden spikes in the number of reports, particularly about quality issues, pharmaceutical errors, and abuse or misuse instances. Results from the method used on the EudraVigilance database were encouraging7.

**Risk assessment for negative effects following medication exposure**

The association between exposure to an investigational pharmaceutical product and the likelihood of adverse events has also been predicted using predictive algorithms. Niebecker8, for instance, described the connections between afatinib exposure and the trajectories of diarrhea and rash/acne adverse events with the ultimate goal of creating a modeling framework that would allow prospective comparison of dosage approaches and trial designs with regard to safety. Another instance is the use of predictive algorithms to anticipate adverse effects following the treatment of rituximab to patients with hematologic malignancies9.

Depending on the machine learning technique used, many approaches to predictive analysis have been used. Using a neural network model, machine learning has been used to forecast the likelihood that an adverse event would occur when a medicine is prescribed.10

Clinical development and postmarket signal detection using predictive models

To determine if safety signals found in first-in-human studies were more likely the product of chance or the drug under study, other authors created a model. Depending on the features of the individual and the study, the model estimates how likely an occurrence is to be the result of chance11.

To effectively identify signals resulting from adverse drug reactions in laboratory settings, a variety of predictive modeling techniques, including random forest, L1 regularized logistic regression, support vector machines, and neural networks, were combined. In order to create a machine learning model, the authors integrated features from each of the modeling strategies. For signal detection purposes, the deployment of this model to an environment with an electronic health record was deemed successful12.

The detection of negative drug reactions has been studied using supervised machine learning signal detection techniques. Sequence symmetry analysis has been utilized to identify signs of adverse drug reactions in the world of medicine dispensing data. This thorough study demonstrates how SSA13 is well-complemented by a gradient boost classifier.

**Specific subpopulations like hospitalized patients**

The patients in this case are at a higher risk of having an adverse drug experience during the hospital stay, as determined by the authors' use of mathematical models to predict the likelihood of hazardous drug experiences in the surgical setting at the time of hospital admission. Interesting applications of predictive analysis and model creation in risk assessment are shown. A thorough review of risk models that forecast adverse medication occurrences during hospitalization is conducted by the authors of another study on drug safety in hospitals15.

**Prediction of hepatotoxicity and interactions**

Using a multi-dose computational model16, to predict drug-induced hepatotoxicity based on gene expression and toxicological data. Utilizing predictive algorithms to foresee negative drug responses brought on by drug-drug interactions17

**Predictive models for comparative safety**

In order to compare the relative safety of three sulfonylureas and the risk of sudden cardiac arrest and ventricular arrhythmia, Leonard CE et al. used a Cox proportional hazard model18. Any suspicions healthcare professionals (doctors, pharmacists, and dentists) may have about medication side effects they encounter on a regular basis can be reported to the BCPH via the "yellow card" to the BCPH.

However, it is especially crucial to report under the following circumstances:

* Serious side effects include those that have resulted in hospitalization or a lengthened hospital stay, that were life-threatening or fatal, that have resulted in permanent or major disability or the incapacity to work, or that have caused a congenital disease or malformation.
* Unexpected adverse effects: side effects whose origin, severity, and/or progression differ from those listed in the Summary of Product Characteristics (SPC).
* Suspected adverse reactions: reactions that are known to occur but whose frequency, severity, or outcome is unusual.

# Negative consequences happening in the following conditions in particular:

# Reporting side effects from so-called "Black triangle drugs" is especially crucial. These include innovative biological therapies and medications with novel active ingredients. The clinical studies conducted for marketing authorization are primarily intended to demonstrate the efficacy of the medication and have limitations in detecting adverse effects:

# the number of patients included in the studies is typically too low to detect rare adverse effects; the length of the studies is insufficient to detect adverse effects that manifest later;

# the studies typically do not include patients who present a high risk of adverse effects (e.g., pediatric or elderly patients).

# Storage Of Data Collection

Pharmacovigilance is a crucial procedure for pharmaceutical companies and other regulatory agencies since it enables them to keep track on a drug's safety. It is often carried out after a medicine has completed all of the clinical trial stages and been given the green light for usage by the general public. By offering a platform for consumers to share information about their experiences with the medications, one method of gathering data for pharmacovigilance purposes. This could take the shape of a unique website that is simple to find and utilize. It might be challenging to persuade all drug users to record unpleasant drug experiences on the web portal, but the information gathered from the few who do may be helpful.

Pharmacovigilance can also benefit from input from primary care doctors. When a doctor prescribes such a drug, it is typically their duty to check in on the patient and assess how they are doing. Bringing a side effect to the attention of the party conducting pharmacovigilance is possible if it is noticed and linked to the medicine in question. The primary care doctors must be made aware of the importance of this information, what to watch out for, and how to record it if this is to be successful. Data on pharmacovigilance can also be obtained directly from patients who are getting hospital-dispensed medications. This works especially well with IV medications, which must be administered inside of a hospital for patient safety. The task of gathering information about the side effects that patients have experienced as a result of using the medication can subsequently be assigned to a specific person.

The information about ADEs that is gleaned from short-term clinical trials could be greatly improved by data mining drug safety record databases, the medical literature, and other digital resources.3 In addition, data mining for pharmacovigilance may offer a "early warning system" that could identify drug safety risks earlier than with conventional techniques3.

Digital Pharmacovigilance in Regulatory Frameworks

Since it involves important domains like operations, surveillance, systems, and qualified individuals for pharmacovigilance, pharmacovigilance has established itself as a significant and dynamic working field for health-related personnel. Each discipline plays a complicated but connected role. Since the number of clinical trials is growing daily and there are more and more safety concerns about medications, pharmacovigilance is a necessity for the modern era. For the following reasons, pharmacovigilance is an immediate requirement for every nation:

The frequency of drug recall incidents is increasing.

• Preclinical and clinical study safety data are insufficient to support empirical proof.

• Because the sample size of clinical trial stages is so small, it might be quite difficult to detect the most uncommon adverse effects.

• Lack of understanding regarding vulnerable populations that are left out of clinical trials, including infants, children, the elderly, pregnant women, nursing mothers, and lactating women.

• The practice of polypharmacy.

• Failure to take into account factors affecting the patient, such as comorbidities, drug-drug interactions, and drug-food interactions.

• Noncompliance with prescribed treatment.

• Lack of knowledge about problems with PV and medication safety among patients, medical professionals, pharmaceutical corporations, and regulatory organizations.

The aforementioned factors increase the importance of PV because there is a lot of data that needs to be reported, gathered, and analyzed. This calls for a team of subject matter experts who can efficiently identify drug-related risks and support keeping a drug on the market throughout its lifecycle by regularly updating their risk management strategies for patients' safety and wellbeing. A variety of cultural, geographic, and medical practices can be found across the continent of Asia. Consequently, pharmacovigilance in Asia needs to be unified and standardised. In terms of the idea of pharmacovigilance, the West has made greater progress than Asia. Since clinical trials and clinical research activities are rapidly increasing throughout Asia, there is a tremendous need to determine and put into action efficient pharmacovigilance procedures.

South Korea's regulatory framework for pharmacovigilance

The Korea Ministry of Food and Drug Safety established the spontaneous reporting mechanism for ADR in 1988. Korea joined the WHO-UMC in 1992 and has participated in global drug surveillance ever since. Korea started post marketing surveillance, a re-examination of the security of recently approved medications, in 1995. The web-based reporting system was made available for reporting adverse events in the year 2000. Since 2003, it has been mandatory for all manufacturers and pharmacists to notify the MFDS of any adverse drug reactions (ADRs) within 15 days of the ADR's occurrence.

In order to encourage spontaneous ADR coverage, the Ministry of Food and Drug Safety designated three university hospitals as Korean Regional PV Centers in 2006. RPPVs were made necessary for all pharmaceutical companies to designate in 2007. In 2009, a well-established PV network with 15 RPVCs was built in Korea. A national concurrent medication use review system was created in 2010 for both doctors and pharmacists. It is a real-time screening system that includes drug-drug interactions, drug-age contraindications, and other topics. The Adverse Drug Reaction Reporting System was introduced in Korea by Korea MFDS in 1988. Since that time, both healthcare professionals and patients have reported spontaneous ADRs. Despite lower reporting rates over the first ten years, Korea has been able to speed up the process after the founding of KIDS (Korea Institute of Drug Safety and Risk Management) in 2012. As a result, KIDS has significantly aided Korean Pharmacovigilance. KIDS uses the WHO-UMC scale to identify signals. Additionally, it makes use of a variety of data mining methods, such as Bayesian Confidence Propagation Neural Networks. Specific regulatory actions, such label changes, can be made as a result of the detection of possible signals. The HIRA database and hospital electronic medical record databases are being used in data mining methodologies for a more thorough investigation of drug use and disease recurrence. The task of assessing causation is also handled by KIDS, which use a range of algorithms based on decision criteria including challenge, dechallenge, and rechallenge data, as well as prior bibliographic information and other aetiologic alternatives. Pharmacoepidemiologic methods like cross-sectional, case-crossover, case-control, and other cohort studies are employed for causality evaluation and signal confirmation. An authorized, planned, and ongoing program that examines, analyzes, and interprets drug usage trends in a specific health care delivery system in comparison to set standards is what is meant by a data utilization review, according to well-established definitions.

The Drug Utilization Review was developed to lower prescription errors and raise the standard of pharmaceutical care. A DUR notifies physicians and pharmacists of the potential side effects that patients may experience after taking their drugs.

**Singapore's pharmacovigilance regulatory framework**

The organization joined the WHO International Drug Monitoring Program in 1994, becoming its forty-first participant. Singapore's Health Science Authority, a drug regulatory body, monitors adverse events related to therapeutic items there. Patients, healthcare professionals, and industry can all voluntarily report adverse events involving therapeutic products, vaccines, complementary therapeutic goods to the HSA. The following adverse occurrences are suitable for reporting: Any negative impacts connected to the usage of new health products, which are ones that have been available in Singapore's market for under five years.

Despite the fact that they are well-known, all grave unfavorable incidents. Consequences that are unanticipated and may not match the product's label or box insert. Healthcare professionals have two options for reporting adverse events:

* they can do so manually by filling out specific color-coded forms and mailing them to the HSA's Vigilance and Compliance Branch at [productsafety@hsa.gov.sg](mailto:productsafety@hsa.gov.sg).
* YELLOW FORM: medicinal substances and supplementary therapeutic items.

Vaccines are in BLUE FORM.

Advanced therapeutic products are in GREEN FORM.

Importers, distributors, retailers, and registrants of therapeutic products are all required to declare all material adverse effects related to their products. The initial report submission requires the following details:

a recognized journalist or healthcare professional.

a patient who can be identified.

unfavorable outcome.

a potential item.

Thailand's pharmacovigilance regulatory framework

Thailand's pharmacovigilance system was established in 1983. The Food and Drug Administration founded the national center, and the ADR monitoring program is its main focus. From the first 176 reports from multiple tertiary institutions in the first year, with pharmacists functioning as the primary reporter, the number of reports has climbed to more than 50,000 annually. Work sphere includes pharmacies, hospitals from community hospitals to tertiary hospitals to university and research centre. The United States Agency for International Development and other Asian countries have taken the initiative to evaluate Thailand's pharmacovigilance system. The project's expertise and learning experiences can serve as a foundation and guiding principles for the pharmacovigilance systems of other nations in addition to helping the countries under study. The following laws apply to pharmacovigilance activities:

Thailand's drug laws and policies are governed by the Drug Act of 1967.

National Drug Policy (2011): A Strategy for the Development of the National Drug System, 2012–2016.

Thailand formally enrolled in the WHO program in 1984. It employs the E2B compliance INTDIS format for ICSR documentation. ATC codes for medications, ICD-10 for indications, and WHO-ART (Adverse Reaction language) were all utilized in medical language.

* The PV database has the following types of reports:
* Unplanned reports,
* adverse event reports following immunization,
* Active surveillance reports,
* Product quality reports,
* PURR, and
* information from PHPS.

Enhancing Adverse Event Reporting and Monitoring

When a new drug or therapy is being tested, an adverse event is a sudden issue that arises. It can range from mild to severe and may be brought on by the medicine itself or something else, according to the National Cancer Institute. Here, we examine the reasons behind the persistently low rate of adverse event reporting and how technology and better protocols might streamline the procedure.

Insufficient AE Reporting

Reporting of AEs is not only subject to biases, but it also frequently goes unreported. For significant adverse events (SAEs), in particular. According to clinical trial standards, researchers are required to immediately report SAEs to the sponsor, who then notifies the FDA within 15 days. Neuer claims that reporting is still troublesome and frequently does not appear at all in articles that are published.

Intervention to Promote AE Reporting

Poor AE reporting rates necessitate the use of appropriate interventions and training. In a study that was published in the journal Frontiers in Pharmacology, researchers argue that frequent interventions and encouragement to report adverse events are crucial. They put their idea to the test in a children's hospital in Israel, where they developed an interventional program and compared it to a control period to ascertain which medications cause adverse effects (AEs). Over the course of three months, the intervention study gathered data. After that, they made a comparison using data acquired for 12 months prior to and following the study. The 12-month period before to intervention displayed a 0% AE report rate, according to the researchers. During the intervention, it rose to 46 reports, but in the year following, it sharply dropped. Consequently, it is concluded that frequent interventions and training are necessary.

Even in countries with official mechanisms for reporting adverse drug reactions (ADRs), a more recent study indicated that reporting rates are low. ADR reporting did, however, increase as a result of initiatives to inform healthcare professionals and hospital teams about when and how to report ADRs.

Collaboration and Stakeholder Engagement

This resource book seeks to assist practitioners and stakeholders in gaining a deeper understanding of how to approach and structure a collaborative process by outlining the fundamentals of collaboration, offering a variety of tools, and reporting on a number of case studies from across the world. Stakeholders are urged to make use of the concepts and knowledge presented here to forge fresh and inventive connections with the people and organizations that can support the realization of collaboration. The process of stakeholder collaboration will go through several revisions.

Any individual, team, or organization that influences or is impacted by a certain problem or result is referred to as a stakeholder. In this book, "stakeholders" refers to individuals, organizations, or social groups that participate in or are impacted by decisions about biodiversity conservation-related issues. Despite the seeming simplicity of this concept, it might be challenging to provide a clear response to questions like these: "The people" are who? What exactly is a "institution"? What exactly constitutes a "social group"? But in order to find and engage the appropriate stakeholders, these questions must be addressed.

Exist several kinds of stakeholders?

Depending on how they use and have historically interacted with resources, different interest groups will have varying stakes in their management. Primary stakeholders are those who are at the center of any conservation movement due to their positions of power, authority, responsibility, or claim to the resources. They must take part in any activity because the outcome will directly affect them. entities at the local level of the community, business interests, and regional and federal government entities can all be regarded as primary stakeholders. By virtue of the influence they have, this category of stakeholder also includes those who have the potential to effect collaborative results even though they might not personally be impacted. Those with a secondary stake in the result are those who are not directly interested. The consumer, who cares about a product's continued availability, the employee of a company, who worries about job security, or the tour operator, who wants to know if a destination for ecotourism will still be reachable by tourists, are a few examples of secondary stakeholders depending on the issue. These stakeholders might need to be included in cooperation processes, but because of how minor their function is in comparison to the key stakeholders', they might only need to be involved occasionally.

Due to their power and resources, opposing stakeholders may be able to have a negative impact on the results. It is critical to engage them in open communication despite the fact that they may adversely affect various parts of conservation planning, especially in the beginning. Even Women, indigenous peoples, and other disadvantaged and disenfranchised groups are examples of marginalized stakeholders who may really be primary, secondary, or opposition stakeholders but who may not have the recognition or ability to take part in collaborative initiatives equally. Always make an extra effort to assure their engagement. Determining the amount of time and assistance needed to enable them to arrange themselves and take part in a collaborative process requires strategic forethought. Though conservation organizations are becoming more aware of how crucial it is to work with their opponents, they have little practical experience in this area. If conservation is to be successful, this will undoubtedly change over time.

Future Perspectives and Innovations

Global pharmacovigilance systems are undergoing considerable change as a result of technology improvements, an increase in the amount of data that authorities and businesses have access to, and a rise in patient involvement in healthcare decision-making. Pharma firms continually contend with a rising number of changes in pharmacovigilance and regulatory compliance: more data from more sources, more products in more places, and constantly shifting reporting requirements.

The need to analyze more data as rapidly as feasible, to monitor risks more thoroughly, and to appropriately report unfavorable events globally increases as a result of these changes.

We think that increased communication between regulators, patients, and medical practitioners, as well as more intelligent data gathering and reporting of potential adverse events, will be crucial components of pharmacovigilance in the future.

In accordance with the laws of the relevant country, our pharmacovigilance department is made up of highly educated, competent, and compliant professionals with the required organizational and technical assistance to satisfy the particular demands of customers.

**REFERENCES**

1. World Health Organization, 2002. The importance of pharmacovigilance.
2. Palaian, S., Khanal, S., Alam, K., & Poudel, A. (2009). Introducing pharmacovigilance to postgraduate pharmacy students in Nepal. American Journal of Pharmaceutical Education, 73(6), Article-number.
3. van Eekeren, Rike, Lean Rolfes, Andries S. Koster, Lara Magro, Gurumurthy Parthasarathi, Hussain Al Ramimmy, Tim Schutte, Daisuke Tanaka, Eugène van Puijenbroek, and Linda Härmark. "What future healthcare professionals need to know about pharmacovigilance: introduction of the WHO PV core curriculum for university teaching with focus on clinical aspects." Drug safety 41 (2018): 1003-1011.
4. World Health Organization, 2002. The importance of pharmacovigilance.
5. Lindquist, M., 2007. The need for definitions in pharmacovigilance. Drug safety, 30, pp.825-830
6. Mammì, M., Citraro, R., Torcasio, G., Cusato, G., Palleria, C. and Paola, E.D.D., 2013. Pharmacovigilance in pharmaceutical companies: An overview. Journal of Pharmacology and Pharmacotherapeutics, 4(1\_suppl), pp.S33-S37
7. Masurkar, Prajakta. "A need of better pharmacovigilance system in India." Asian J Pharm Clin Res 10, no. 1 (2017): 22-24.
8. Dal Pan GJ. Ongoing challenges in pharmacovigilance. Drug safety. 2014 Jan;37:1-8.
9. Khan, Muhammad Akhtar Abbas, Saima Hamid, and Zaheer-Ud-Din Babar. "Pharmacovigilance in high-income countries: current developments and a review of literature." Pharmacy 11.1 (2023): 10
10. World Health Organization. Pharmacovigilance: ensuring the safe use of medicines. No. WHO/EDM/2004.8. World Health Organization, 2004
11. Kubde, Sneha. "Adverse drug reactions and pharmacovigilance of herbal medicines in India." International Journal of Green Pharmacy (IJGP) 10, no. 1 (2016)
12. Sloane, Richard, Orod Osanlou, David Lewis, Danushka Bollegala, Simon Maskell, and Munir Pirmohamed. "Social media and pharmacovigilance: a review of the opportunities and challenges." British journal of clinical pharmacology 80, no. 4 (2015): 910-920
13. Khattri, Shilpi, V. Balamuralidhara, Kumar TM Pramod, Ravi Valluru, and M. P. Venkatesh. "Pharmacovigilance regulations in India: A Step forward." Clinical Research and Regulatory Affairs 29, no. 2 (2012): 41-45

# From Paper to Pixels: Tracing the Evolution of Pharmacovigilance Technology; <https://ultragenicglobal.com/from-paper-to-pixels-tracing-the-evolution-of-pharmacovigilance-technology/>

# 15.https://ultragenicglobal.com/from-paper-to-pixels-tracing-the-evolution-of-pharmacovigilance-technology/

1. Beninger, P., 2018. Pharmacovigilance: an overview. Clinical therapeutics, 40(12), pp.1991-2004.
2. Suke, S. G., Kosta, P., & Negi, H. (2015). Role of pharmacovigilance in India: An overview. Online journal of public health informatics, 7(2)
3. Signal Detection and Management in Pharmacovigilance ;A hybrid approach to signal detection and management; <https://www.tcs.com/what-we-do/products-platforms/tcs-add/white-paper/signal-detection-management-pharmacovigilance-hybrid->

# Whitepaper: A hybrid approach towards signal management in PV

1. <https://www.europeanpharmaceuticalreview.com/whitepaper/172103/whitepaper-a-hybrid-approach-towards-signal-management-in-pv/>
2. A Hybrid Approach towards Signal Detection and Signal Management for Pharmacovigilance; <https://www.europeanpharmaceuticalreview.com/wp-content/uploads/TCS-WhitePaper-Signal-Detection-and-Signal-Management-for-Pharmacovigilance_2022.pdf>.
3. A Digitalized Future For Pharmacovigilance:<https://www.pharmafocusasia.com/information-technology/digitalised-future-pharmacovigilance>.
4. Digital Health and Big Data Analytics: Implications of Real-World Evidence for Clinicians and Policymakers; https://pubmed.ncbi.nlm.nih.gov/35886214/.

# 3.The impact and use of social media in pharmacovigilance; <https://ddblog.labcorp.com/2018/09/the-impact-and-use-of-social-media-in-pharmacovigilance/>; 4.The value of patient reporting to the pharmacovigilance system; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237689/>

# 5.Patient Reported Outcomes in Pharmacovigilance; <https://link.springer.com/protocol/10.1007/978-1-4939-8818-1_9>

# Wearable biosensors for healthcare monitoring; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183422

1. Mobile Health ; https://www.science.gov/topicpages/m/mobile+health+mhealth.html
2. Recommendations on the Use of Mobile Applications for the Collection and Communication of Pharmaceutical Product Safety Information: Lessons from IMI WEB-RADR; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450855/>
3. Artificial Intelligence and Machine Learning in Pharmacovigilance; <https://www.avenga.com/magazine/artificial-intelligence-machine-learning-pharma/>

# Automation in signal management in pharmacovigilance-an insight; <https://pubmed.ncbi.nlm.nih.gov/33333548/>

# Adverse drug event detection using natural language processing: A scoping review of supervised learning methods; <https://pubmed.ncbi.nlm.nih.gov/36595517/#:~:text=Natural%20language%20processing%20(NLP)%2C,in%20the%20context%20of%20pharmacovigilance>.

1. Alanazi H, Abdullah A, Qureshi K. A Critical Review for Developing Accurate and Dynamic Predictive Models Using Machine Learning Methods in Medicine and Health Care. J Med Syst. 2017;41(4):69. <https://www.ncbi.nlm.nih.gov/pubmed/28285459>.
2. Federer C, Yoo M, Tan A. Big Data Mining and Adverse Event Pattern Analysis in Clinical Drug Trials. Assay Drug Dev Technol. 2016;14(10):557-566. <https://www.ncbi.nlm.nih.gov/pubmed/27631620>.
3. Poleksic A, Xie L. Predicting serious rare adverse reactions of novel chemicals. Bioinformatics. 2018;34(16):2835-2842. <https://www.ncbi.nlm.nih.gov/pubmed/29617731>Ventola C. Big Data and 15. Pharmacovigilance: Data Mining for Adverse Drug Events and Interactions. P T. 2018;43(6):340-351. <https://www.ncbi.nlm.nih.gov/pubmed/29896033>.
4. 16.Caster O, Sandberg L, Bergvall T, Watson S, Norén G. vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real-world use. Pharmacoepidemiol Drug Saf. 2017;26(8):1006-1010. <https://www.ncbi.nlm.nih.gov/pubmed/28653790>.
5. 17.Star K, Sandberg L, Bergvall T, Choonara I, Caduff-Janosa P, Edwards I. Paediatric safety signals identified in VigiBase: Methods and results from Uppsala Monitoring Centre. Pharmacoepidemiol Drug Saf. February 2019. <https://www.ncbi.nlm.nih.gov/pubmed/30767342>.
6. 18.Niebecker R, Maas H, Staab A, Freiwald M, Karlsson M. Modelling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib. CPT Pharmacometrics Syst Pharmacol. January 2019. <https://www.ncbi.nlm.nih.gov/pubmed/30681293>.
7. 19.D’Arena G, Simeon V, Laurenti L, et al. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. Leuk Lymphoma. 2017;58(11):2633-2641. <https://www.ncbi.nlm.nih.gov/pubmed/28367662>.
8. 20.Kasatkin D, Bogomolov Y, Spirin N. [Steps to personalized therapy of multiple sclerosis: predicting safety of treatment using mathematical modeling]. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(8. Vyp. 2):70-76. <https://www.ncbi.nlm.nih.gov/pubmed/30160671>.
9. 21.Clayton G, Schachter A, Magnusson B, Li Y, Colin L. How Often Do Safety Signals Occur by Chance in First-in-Human Trials? Clin Transl Sci. 2018;11(5):471-476. <https://www.ncbi.nlm.nih.gov/pubmed/29702733>.
10. 22.Jeong E, Park N, Choi Y, Park R, Yoon D. Machine learning model combining features from algorithms with different analytical methodologies to detect laboratory-event-related adverse drug reaction signals. PLoS One. 2018;13(11):e0207749. <https://www.ncbi.nlm.nih.gov/pubmed/30462745>.
11. 23.Hoang T, Liu J, Roughead E, Pratt N, Li J. Supervised signal detection for adverse drug reactions in medication dispensing data. Comput Methods Programs Biomed. 2018;161:25-38. <https://www.ncbi.nlm.nih.gov/pubmed/29852965>.
12. 24.Bos J, Kalkman G, Groenewoud H, et al. Prediction of clinically relevant adverse drug events in surgical patients. PLoS One. 2018;13(8):e0201645. <https://www.ncbi.nlm.nih.gov/pubmed/30138343>.
13. 25.Falconer N, Barras M, Cottrell N. Systematic review of predictive risk models for adverse drug events in hospitalized patients. Br J Clin Pharmacol. 2018;84(5):846-864. <https://www.ncbi.nlm.nih.gov/pubmed/29337387>.
14. 26.Su R, Wu H, Xu B, Liu X, Wei L. Developing a Multi-Dose Computational Model for Drug-induced Hepatotoxicity Prediction based on Toxicogenomics Data. IEEE/ACTrans Comput Biol Bioinform. July 2018. <https://www.ncbi.nlm.nih.gov/pubmed/30040651>.
15. 27.Liu R, AbdulHameed M, Kumar K, Yu X, Wallqvist A, Reifman J. Data-driven prediction of adverse drug reactions induced by drug-drug interactions. BMC Pharmacol Toxicol. 2017;18(1):44. <https://www.ncbi.nlm.nih.gov/pubmed/28595649>.
16. 28.Leonard C, Brensinger C, Aquilante C, et al. Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia. Diabetes Care. 2018;41(4):713-722. <https://www.ncbi.nlm.nih.gov/pubmed/29437823>.
17. Data quality management in pharmacovigilance; <https://pubmed.ncbi.nlm.nih.gov/15366974/#:~:text=The%20pharmacovigilance%20data%20processing%20cycle,are%20drawn%20and%20decisions%20made>.

# 2. Data collection, evaluation and measures; <https://www.famhp.be/en/human_use/medicines/medicines/pharmacovigilance/data_collection_evaluation_measures>.

# 3. <https://www.biopharmainstitute.com/faq/how-is-data-collected-for-pharmacovigilance-purposes>.

# 4. Clinical standardization of programs;https://www.cdc.gov/labstandards/csp/index.html.

# 5. Clinical standardization of programs;https://www.cdc.gov/labstandards/csp/csp\_standardization.html

# 6. Vilar S, Friedman C, Hripcsak G, et al. Detection of drug–drug interactions through data mining studies using clinical sources, scientific literature, and social media [published online February 17, 2017] Brief Bioinform. doi: 10.1093/bib/bbx010. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454455/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/28334070)] [[CrossRef](https://doi.org/10.1093%2Fbib%2Fbbx010" \t "_blank)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Brief+Bioinform&title=Detection+of+drug%E2%80%93drug+interactions+through+data+mining+studies+using+clinical+sources,+scientific+literature,+and+social+media+%5bpublished+online+February+17,+2017%5d&author=S+Vilar&author=C+Friedman&author=G+Hripcsak&doi=10.1093/bib/bbx010&)]

# 7. Data privacy (information privacy);https://www.techtarget.com/searchcio/definition/data-privacy-information-privacy.

# 8. Data Security Consideration;https://www.wikitechy.com/tutorial/cyber-security/data-security-consideration

# Pharmacovigilance Regulatory Framework of Three Asian Countries – South Korea, Singapore and Thailand; <https://www.intechopen.com/chapters/85297>.

1. Regional Pharmacovigilance System in Korea. Available from: http://www.drugsafe.or.kr/iwt/ds/en/community/EgovCenterGuide.do [Accessed: November 01, 2022]
2. Biswas P. Pharmacovigilance in Asia. Journal of Pharmacology and Pharmacotherapeutics. 2013;4(SUPPL.1):7-19
3. Shin Y. Spontaneous reporting of adverse drug events by Korean Regional Pharmacovigilance Centers. Pharmacoepidemiology and Drug Safety. 2009;18:910-915
4. Shin Y. New Initiatives for pharmacovigilance in South Korea: Introducing the Korea Institute of Drug Safety and Risk Management (KIDS). Pharmacoepidemiology and Drug Safety. 2014;23:115-122.

# How To Improve the Process of Adverse Event Reporting ;https://www.anjusoftware.com/insights/eclinical/edc/reporting-adverse-events.